CA
ALXO icon

Clearstead Advisors’s ALX Oncology ALXO Stock Holding History

Clearstead Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-177
Closed -$74 – 3094
2025
Q2 		$74 Buy
+177
New +$89 ﹤0.01% 2645

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Clearstead Advisors's ALXO Position: Q3 2025 in Review

Clearstead Advisors sold out of ALX Oncology (ALXO) in Q3 2025, closing a stake of 177 shares — an estimated $74 sold.

Clearstead Advisors first reported a position in ALXO in Q2 2025 and held it in 1 quarter. The position peaked at $74 in Q2 2025. 61 funds tracked by Wall St. Rank hold ALXO as of Q3 2025.

  • Clearstead Advisors reported no remaining ALX Oncology position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 177 ALX Oncology shares in Q3 2025, an estimated $74.
  • Clearstead Advisors first reported a position in ALX Oncology in Q2 2025 and held it in 1 quarter.
  • Clearstead Advisors's ALX Oncology position peaked at $74 in Q2 2025.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.